Calithera Biosciences : Investor Deck

Targeting cancer, differently.

Susan M. Molineaux, Ph.D. | Founder, President & Chief Executive Officer

NASDAQ: CALA

CALITHERA® and the Calithera Logos are trademarks or registered trademarks of Calithera Biosciences, Inc. All rights reserved.

Forward-Looking Statements

This presentation and the accompanying oral commentary contain "forward-looking" statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "believe," "will," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "might," "approximately," "expect," "predict," "could," "potentially" or the negative of these terms or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. All statements other than statements of historical facts contained in this presentation and the accompanying oral commentary are forward-looking statements, and such forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: plans regarding anticipated clinical trials for our product candidates, including CB-228 (sapanisertib), CB-659 (mivavotinib), CB-280, INCB001158 and CB-708, the potential safety, efficacy and other benefits of and market opportunity of product candidates, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, statements relating to future royalties and the development, regulatory and sales milestone payments of INCB001158 and CB-708 in connection with our collaborations with Incyte and Antengene, respectively, and of CB-228 and CB-659 in connection with our asset purchase agreement with Takeda, our intellectual property position and cash needs.

Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The potential product candidates that we develop may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this presentation and the accompanying oral commentary. Such product candidates may not be beneficial to patients or be successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on our stock price. We discuss many of these risks in greater detail under the heading "Risk Factors" contained in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission on November 9, 2021. Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this presentation and the accompanying oral commentary. Any forward-looking statements that we make in this presentation and the accompanying oral commentary speak only as of the date of this presentation. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise.

2

Calithera Today

• Core expertise in oncology, discovering and developing novel small molecule enzyme inhibitors
• • Primary focus is on precision oncology
  • Nimble and well-versed in conducting biomarker-driven early and late stage clinical trials
• Recent addition of two mature mid-stage clinical assets to our pipeline
• • With this acquisition from Takeda Pharmaceuticals, we fully own all development and commercial rights
  • We have developed a new biomarker-driven clinical strategy for both compounds
  • Potential for rapid approval paths in genetically-defined patient populations
• Robust discovery engine creating a preclinical pipeline of synthetic lethal targets
• Experienced leadership team across a fully-integrated biopharmaceutical company
• Expected cash runway into 2023 sufficient to reach next clinical milestones on both new programs

3

Strong Management

Experienced Leadership

Susan Molineaux,	Emil Kuriakose, M.D.	Stephanie Wong	Sumita Ray	Christopher
Ph.D.	Chief Medical Officer	Chief Financial Officer	Chief Legal &	Molineaux, Ph.D.
Founder, President &		& Secretary	Administrative Officer	Senior Vice President
			of Development
Chief Executive Officer

Frank Parlati,	Eric Sjogren, Ph.D.	Susan Demo, Ph.D.	Matthew Gross	Allison Dillon, Ph.D.
Ph.D.	Senior Vice President of	Senior Vice President of	Vice President of	Senior Vice President of
Senior Vice President	Drug Discovery	R&D Operations	Business Development	Commercial & Portfolio
of Research				Strategy

Board of Directors

Sunil Agarwal, M.D.

Chief Development Officer, Sana Biotechnology

Jonathan G. Drachman, M.D.

CEO, Neoleukin Therapeutics

Scott Garland

CEO, PACT Pharma

Suzy Jones

Founder & Managing Partner, DNA Ink

Susan Molineaux, Ph.D.

Founder, President & CEO, Calithera

Keith Orford, M.D., Ph.D.

CMO, FogPharma

Deepa Pakianathan, Ph.D.

Managing Member, Delphi Ventures

Blake Wise

CEO, Novome Biotechnologies

H. Ward Wolff

Former CFO, Sangamo Therapeutics

4

New Clinical and Preclinical Pipeline

Mivavotinib

Sapanisertib

Synthetic Lethality

SYK inhibitor	mTORC1/2 inhibitor	VPS4A/VPS4B (ATPases)
Biomarker-defined clinical	Biomarker-defined clinical	Preclinical program: paralogs
activity in ABC DLBCL	activity in NRF2m sqNSCLC	Inhibitor to target tumors with
Ph 2A/2B trial in ABC DLBCL	Ph 2A/2B trial in NRF2m	one deleted paralog
initiating in 1Q22	sqNSCLC initiating in 1Q22	NGS biomarker defined
Ph2a single agent data	Ph2a single agent data
expected 4Q22-1Q23	expected in 4Q22-1Q23	Potential for large market

5